Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.
These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DOJoPAWP.js ...
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported a larger-than-expected loss for Q1 FY2025, with earnings per share (EPS) at -$1.39, missing the forecast of -$0.39. Revenue also fell short, totaling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback